top of page

October 2024 // Funding & Investment

Synendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510


Synendos AG is excited to announce that it has been awarded a grant under the highly competitive Start-Up Innovation Project (SIP) scheme of Innosuisse which aims to support cutting-edge Swiss innovation. The Innosuisse SIP initiative fosters groundbreaking science-based projects with high socioeconomic potential.


The project has a total budget of CHF 2.9 million. This funding will be pivotal to supporting our mission to uncover the potential of our novel SERI mechanism in treating neuropsychiatric disorders such as PTSD, through the study of our Phase 1 candidate, SYT-510 in clinical models of anxiety and stress.


We are grateful to Innosuisse for the recognition and support of our innovative approach.

Recent Posts

See All

April 2021 // Investment

Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of...

October 2020 // Funding

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).

Comentarios


bottom of page